Peresolimab PD-1 agonist in RA Phase 2 RCT Primary endpoint met w/ > improvement DAS28CRP Wk12 Also greater improvement of CDAI in both treated grps TEAEs PBO 37% PER 300mg 40% PER 700mg 35%, 1 serious AE in PER 700mg https://t.co/QtclWIWAw9 Abs#L03 #ACR22 @Rheumnow https://t.co/bLHP4JuNjt